In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts
Findings provide support for hypothesized mechanism of action of anti-gene, which is designed to not degrade the DMPK transcript
Data further validate the potential of the PATrOL platform to develop highly targeted therapies that increase, decrease or change causal protein function
NeuBase management to hold conference call and webcast today, December 16, at 8:00 a.m. EST
PITTSBURGH, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBases anti-gene approach to comprehensively treat the underlying cause of DM1.
Despite the fact that the genetic basis of DM1 is well understood today, there is still an urgent need to find the first genetically-targeted, disease-modifying treatment option for affected patients, said Curt Bradshaw, Ph.D., Chief Scientific Officer of NeuBase. DM1 is caused by a genetic mutation in the DMPK gene leading to mis-splicing of a broad spectrum of genes and DMPK protein insufficiency. A treatment option that addresses mis-splicing while retaining functional DMPK protein levels may be key to treating all aspects of DM1.
Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, added, Using our proprietary PATrOL platform, we have designed a first-in-class anti-gene candidate that selectively binds mutant DMPK mRNA and opens its hairpin secondary structure, as opposed to a mechanism of action that explicitly degrades the mutant and wild-type transcripts indiscriminately, making it a unique option for the treatment of DM1. These in vitro and in vivo data both support our hypothesized mechanism of action and demonstrate rapid and broad resolution of the mis-splicing that is the primary cause of DM1.
This is the second set of positive data that weve announced in 2020 for our PATrOL-enabled therapies, which we believe serves as proof of concept that further validates our technologic foundation. With a single unified platform, we believe we can increase, decrease or change protein function of potentially any nucleic acid target, unique among genetic medicine approaches. We are excited by the progress we have made and look forward to providing additional updates on our platform and pipeline of programs at an R&D day in the first half of 2021.
In vitro data highlights in DM1 patient-derived fibroblasts:
In vivo data highlights in the HSALR transgenic mouse model of DM1 that expresses high levels of mutant CUG-repeat-containing mRNA (HSA) in skeletal muscle:
DM1 is a rare, autosomal dominant repeat expansion disorder characterized by progressive muscle wasting and weakness. It also affects the central nervous system (CNS) and heart. DM1 is caused by CTG nucleic acid repeats in the DMPK gene that produce a hairpin structure in the transcribed DMPK mRNA. The hairpin structure sequesters critical splice regulators and results in the mis-splicing of multiple gene transcripts. Furthermore, the binding of splice regulators traps the mutant DMPK mRNA in the nucleus, resulting in DMPK protein haploinsufficiency, or half the level of protein that is needed for normal function, which is thought to exacerbate the CNS and cardiac symptoms that are characteristic of DM1 (as knock-out mice for Dmpk show both severe cardiac conduction defects as well as issues with neuronal cytoskeletal remodeling manifesting in aberrant long-term potentiation). The prevalence of DM1 is >5/100,000 in the general population. There are currently no approved treatments for DM1.
Conference Call and Webcast Details
NeuBase Therapeutics, Inc. will discuss these data during a webcasted conference call with slides today, December 16, 2020, at 8:00 a.m. EST. To access the webcast, please click here. An archived recording of this presentation will be available following the call through the IR Calendar page on the Investors section of the Companys website, http://www.neubasetherapeutics.com.
About NeuBase Therapeutics, Inc.NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase's designer PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit http://www.neubasetherapeutics.com.
Use of Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to the potential significance and implications of the Companys positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the risks that prior data will not be replicated in future studies; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
NeuBase Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com OP: (617) 430-7576
NeuBase Media Contact:Cait Williamson, Ph.D.LifeSci Communicationscait@lifescicomms.com OP: (646) 751-4366
Excerpt from:
- Panicked Elon Musk Reportedly Begging Engineers Not to Leave - November 20th, 2022
- NASA Drops Stunning New James Webb Image of a Star Being Born - November 20th, 2022
- Elon Musk Locks Twitter Employees Out Office, Then Asks Them to Meet Him on the 10th Floor - November 20th, 2022
- Former Facebook Exec Says Zuckerberg Has Surrounded Himself With Sycophants - November 20th, 2022
- NASA Orders Press Not to Photograph Launch Site After Moon Mission Takes Off - November 20th, 2022
- FDA Gives First Go Ahead for Lab Grown Meat Product - November 20th, 2022
- "Elon" Plummets in Popularity as a Baby Name for Some Reason - November 20th, 2022
- Celebrities' Bored Apes Are Hilariously Worthless Now - November 20th, 2022
- Experts Baffled by Why NASA’s “Red Crew” Wear Blue Shirts - November 20th, 2022
- Sam Bankman-Fried Admits the "Ethics Stuff" Was "Mostly a Front" - November 20th, 2022
- Twitter Claims Video of Moon Rocket Launch Is Revenge Porn - November 20th, 2022
- Ticketmaster May Have Finally Met Its Match: Furious Swifties - November 20th, 2022
- Celebrities Are Officially Being Sued by FTX Retail Investors - November 20th, 2022
- NASA Tells Astronauts That Tweeting Isn't As Important as Staying Alive - November 20th, 2022
- Startup Says It's Building a Giant CO2 Battery in the United States - November 20th, 2022
- Experts Excoriate NASA Report Claiming James Webb Wasn't Homophobic - November 20th, 2022
- Behind the Lawsuit Against Celebs Who Shilled FTX Before Its Spectacular Meltdown - November 20th, 2022
- Amazing Map Lets You Scroll Through the Entire Known Universe - November 20th, 2022
- So Many People Are Using a Diabetes Drug for Weight Loss That Actual Diabetics Are Having Trouble Getting It - November 20th, 2022
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022
- Double Duty: Early Research Reveals how a Single Drug Delivers Twice the Impact in Fragile X - URMC - June 29th, 2022
- New Technology Helps Reveal Inner Workings of Human Genome - Weill Cornell Medicine Newsroom - June 29th, 2022
- HIV drug may improve cognitive function in people with Down syndrome - Study Finds - June 29th, 2022
- Novartis hunting for sickle cell cure with Precision deal - BioPharma Dive - June 29th, 2022
- Ambys Medicines Announces Formation of Clinical and Scientific Advisory Boards with Leading Liver Disease and Cell and Gene Therapy Experts - Business... - June 29th, 2022
- A Functional Medicine Approach to Detoxing the Body - Magazine of Santa Clarita - June 29th, 2022
- Meet the company trying precision medicine for autism | Spectrum - Spectrum - June 29th, 2022
- CRISPR, 10 Years On: Learning to Rewrite the Code of Life - The New York Times - June 29th, 2022
- After 9 Years in Trials, Roche's Crenezumab Stalls Out - Being Patient - June 29th, 2022
- Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results - GuruFocus.com - June 29th, 2022
- Dr. Stephen Kingsmore to receive Luminary Award at 2022 Precision Medicine World Conference - EurekAlert - June 29th, 2022
- Do agri-businesses 'control' agriculture? The emerging gene-editing revolution in Latin America is challenging that belief - Genetic Literacy Project - June 29th, 2022
- New hope for IVF patients as global study published in Human Reproduction shows AI can effectively assess genetic integrity of embryos USA - English -... - June 29th, 2022
- Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear... - June 29th, 2022
- Realizing Gene Therapy and Cell Regeneration in Heart Disease - BioSpace - January 25th, 2022
- Small children getting less sick from Omicron; Genetic mutation protects against severe COVID - Reuters - January 25th, 2022
- Bionano Genomics Announces its Support for the AGMG - GlobeNewswire - January 25th, 2022
- Discovery of hundreds of genes potentially associated with ALS may steer scientists toward treatments - Stanford Medical Center Report - January 25th, 2022
- Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology - Business Wire - January 25th, 2022
- EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and... - January 25th, 2022
- Roche revives a closely watched Huntington's disease drug - BioPharma Dive - January 25th, 2022
- WashU part of $65 million NIH study of schizophrenia in young people Washington University School of Medicine in St. Louis - Washington University... - January 25th, 2022
- UTSW researchers take new approach to fight viral infections - UT Southwestern - January 25th, 2022
- Promising ALS therapy moves closer to clinic - EurekAlert - January 25th, 2022
- 5 Slides We're Discussing: Gene therapy and the promise for rare disease - State of Reform - State of Reform - January 25th, 2022
- Worldwide Genomic Cancer Panel and Profiling Industry to 2024 - Next Generation Sequencing Fuels a Revolution - PRNewswire - January 25th, 2022
- Genetic Research Shows Rapid Immune Response in Children Protects Them From COVID-19 - SciTechDaily - January 25th, 2022
- British Labs Supply the World with Genetic Information about COVID-19 - VOA Learning English - January 25th, 2022
- Xenotransplantation and the future of medicine - Hindustan Times - January 25th, 2022
- Which Drugs Will Survive Climate Change? We Investigated. - VICE - January 25th, 2022
- Sema4 : The Positives (and Negatives) of Medical Testing - marketscreener.com - January 25th, 2022
- UC Davis Health's partnership in telegenomics improves accessibility to genetic medicine with telemedicine robots - The Aggie - The Aggie - September 5th, 2021
- Could gene therapies be used to cure more people with HIV? - aidsmap - September 5th, 2021
- What to expect at the FDA's two-day meeting on gene therapy safety - BioPharma Dive - September 5th, 2021
- Global DNA Sequencing Report 2021: There is a Move Toward a More Consumer-Focused Model - Yahoo Finance - September 5th, 2021
- Agathos Biologics Receives $900,000 from the North Dakota Bioscience Innovation Grant Program - Yahoo Finance - September 5th, 2021
- New gene therapies may soon treat dozens of rare diseases, but million-dollar price tags will put them out of reach for many - The Conversation US - September 5th, 2021
- An ethical analysis of divergent clinical approaches to the application of genetic testing for autism and s... - Physician's Weekly - September 5th, 2021
- Intense exercise could trigger ALS in those with genetic risk - Livescience.com - September 5th, 2021
- UT Southwestern selected top health care employer in Texas by Forbes - UT Southwestern - September 5th, 2021
- Opinion: Gene editing can be leveraged for the greater good with appropriate regulations - Varsity - September 5th, 2021
- Beefing up livestock disaster assistance | Farm & Ranch | willistonherald.com - Williston Daily Herald - September 5th, 2021